1 0.9% Sodium Chloride (infusion, solution)

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredient
9g/L (0.9%) sodium chloride (USP), in water for injection.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Infusion, solution, in VIAFLO bag.

0.9% Sodium Chloride infusion solution is a colourless or white crystal and is freely soluble in water and practically insoluble in anhydrous ethanol.

0.9% Sodium Chloride infusion solution preparations are clear, colourless, practically free from visible particles, sterile and non-pyrogenic solutions. The concentrations of the active ingredients dissolved in a litre of Water for Injection are shown in the table in section 6.5. They do not contain an antimicrobial agent or added buffer. However, during the sterilisation step a small amount of hydrochloric acid may leach out resulting in a slightly acidic solution with a pH of 4.5 – 7.0. 0.9% Sodium Chloride solutions are isotonic as indicated by their osmolarity shown in the table in section 6.5.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

0.9% Sodium Chloride infusion solutions is indicated:

- As a vehicle for the administration of parenteral drugs
- Also utilised as an extracellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.

4.2 Dose and method of administration

0.9% Sodium Chloride is for intravenous infusion. To be used as directed by the doctor.

Dosage, rate, and duration of administration are to be individualised and depend upon the indication for use, the patient’s age, weight, clinical condition, and concomitant treatment, and on the patient’s clinical and laboratory response to treatment.

Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration whenever solution and container permit. The solution should be clear and free from particles. Do not administer unless solution is clear and seal is intact. Additives may be incompatible. See section 6.2. The instructions for use of the medication to be added and other relevant literature must be consulted. Consult with a pharmacist, if available. If in the informed judgment of the doctor, it is deemed advisable to introduce additives, use aseptic technique.

When other electrolytes or medicines are added to this solution, the dosage and the infusion rate will also be dictated by the dose regimen of the additions.
The product should be used for one patient on one occasion only. Any unused portion should be discarded.

**Directions for use of VIAFLO plastic container**

**Warning.** Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container.

Pressurising intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.

Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.

**To open**

Tear overwrap down side at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilisation process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard the product as sterility may be impaired. If supplemental medication is desired, follow directions below.

**Preparation for Administration**

**0.9% Sodium Chloride** infusion is a sterile preparation. Thus, aseptic technique must be applied throughout the administration.

1. Suspend container from eyelet support.
2. Remove plastic protector from outlet port at the bottom of container.
3. Attach administration set.

**To add medication during solution administration**

**Warning. Additives may be incompatible** see section 4.4, 4.5 and section 6.2.

**To add medication before solution administration**

Supplemental medication may be added with needle through the medication injection port. To proceed, swab medication site (port) with alcohol swab. Using a syringe with 0.63 to 0.80mm needle, puncture resealable medication port and inject. Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly. Close clamp on the set. Prepare medication port. Using a syringe with 0.63 to 0.80mm needle, puncture resealable medication port and inject. Remove container from IV pole and/or turn to upright position. Evaluate both ports by squeezing them while container is in the upright position. Mix solution and medication thoroughly. Return container to in use position and continue administration.

The solutions contain no antimicrobial agents, and are for single use in only one patient. Unused portions must be discarded.

**4.3 Contraindications**

The use of **0.9% Sodium Chloride** infusion requires careful evaluation of risks and benefits by the attending physician. It must not be used in the following conditions unless the physician has determined that potential benefits outweigh risks:
• congestive heart failure
• severe impairment of renal function
• clinical states in which there exists oedema with sodium retention
• liver cirrhosis
• irrigation during electrosurgical procedures.

See section 4.4.

4.4 Special warnings and precautions for use
The safety of the VIAFLO plastic bag container has been shown in tests with animals according to the USP biological tests for plastic container, as well by tissue culture toxicity studies.

In a dilute condition, osmolality/L is approximately the same as osmolality/kg.

General
Clinical evaluation and appropriate laboratory determinations are essential to monitor renal function, changes in fluid balance, electrolyte concentration and acid-base balance.

0.9% Sodium Chloride infusion may cause fluid and/or solute overload resulting in overhydration/hypervolaemia and, for example, congested states, including central and peripheral oedema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injections. The risk of solute overload causing congested states with peripheral and pulmonary oedema is directly proportional to the electrolyte concentration administered.

Clinical evaluation and periodic laboratory determinations may be necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.

Thus, caution should be exercised in patients with hypertension, heart failure, cerebral oedema, renal disease, pulmonary or peripheral oedema, pre-eclampsia, liver cirrhosis, conditions associated with sodium retention, and in geriatric patients, and infants.

0.9% Sodium Chloride infusion should be used with caution in patients receiving corticosteroids or corticotrophin, because of potential sodium retention. Given that there is a possibility of systematic absorption of irrigation solutions, the same precautions apply. Displaced catheters or drainage tubes can lead to irrigation or infiltration of unintended structures or cavities. Excessive volume or pressure during irrigation of closed cavities may result in distention of tissues.

0.9% Sodium Chloride infusion should be used with particular caution, if at all, in patients with or at risk for hypernatraemia, hyperchloraemia, hypervolaemia and conditions that may cause sodium retention, fluid overload and oedema (central and peripheral).

Its use may result in electrolyte abnormalities, including hypokalaemia and hyperkalaemia, see section 4.8 and section 4.9.

Rapid correction of hyponatraemia and hypernatraemia is potentially dangerous.

0.9% Sodium Chloride infusion should be used with caution in patients receiving corticosteroids or corticotrophin, because of potential sodium and fluid retention.
Hypersensitivity/infusion reactions, including hypotension, pyrexia, tremor, chills, urticaria, rash, and pruritus, have been reported.

Stop the infusion immediately if signs or symptoms of hypersensitivity/infusion reactions develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.

**Paediatric use**
Safety and effectiveness of **0.9% Sodium Chloride** in paediatric patients have not been established by adequate or controlled trials. In paediatric use, doses are calculated for each patient based on clinical condition, including body weight, and laboratory data.

Plasma electrolyte concentrations should be closely monitored in the paediatric population because of their impaired ability to regulate fluids and electrolytes.

**Use in the elderly**
There are no adequate or well-controlled studies of **0.9% Sodium Chloride** infusion in subjects aged 65 and over to determine whether they respond differently from younger subjects.

When selecting the type of infusion solution and the volume/rate of infusion for an elderly patient, consider that elderly patients are generally more likely to have cardiac, renal, hepatic, and other diseases or concomitant medicine therapy.

In general, dose selection for an elderly patient should be cautious as it is known that sodium chloride is substantially excreted by the kidney, and the risk of toxic reactions to this medicine, may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and thus renal function may be monitored.

**4.5 Interaction with other medicines and other forms of interaction**
**0.9% Sodium Chloride** infusion should not be administered simultaneously with blood products through the same administration set, because of the possibility of pseudo-agglutination or haemolysis. The container label for this product bears the statement: do not administer simultaneously with blood.

If **0.9% Sodium Chloride** infusion is used as a vehicle for a drug delivery, a thorough review of the prescribing information document(s) of such medicine(s) should be made to ensure that no incompatibility might occur. Salting out, i.e. a precipitation of organic base drug may occur in the presence of salt.

Caution is advised in patients treated with lithium. Renal sodium and lithium clearance may be increased during administration of **0.9% Sodium Chloride** resulting in decreased lithium levels.

**4.6 Fertility, pregnancy and lactation**

**Fertility**
There are no fertility data presented.

**Use in pregnancy (Category A)**
There are no adequate and well-controlled studies of **0.9% Sodium Chloride** infusion in animals or in pregnant women. However, **0.9% Sodium Chloride** infusion contains no components known to have adverse effects on the foetus at physiological concentrations.

Physicians should carefully consider the potential risks and benefits for each specific patient before administering **0.9% Sodium Chloride**.
Use in lactation
Following intravenous administration, a fraction of sodium and chloride ions is expected to be excreted into human milk. However, at physiological concentrations, neither of these ions is known to have adverse effects on a breastfeeding baby.

Physicians should carefully consider the potential risks and benefits for each specific patient before administering 0.9% Sodium Chloride.

4.7 Effects on ability to drive and use machines
There is no information on the effects of 0.9% Sodium Chloride on the ability to operate an automobile or other heavy machinery.

4.8 Undesirable effects
Adverse effects, which may occur because of the solution or the technique of administration, include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation. Excessive administration of sodium chloride causes hypernatraemia, resulting in dehydration of internal organs, hypokalaemia and acidosis, see section 4.9.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Inappropriate use of 0.9% Sodium Chloride infusion may cause fluid or solute overload resulting in electrolyte abnormalities, overhydration, congestive conditions including central, peripheral or pulmonary oedema electrolyte imbalances and acid-base imbalance.

Post-marketing adverse reactions
The following adverse reactions have been reported in the post-marketing experience, listed by MedDRA System Organ Class (SOC), then, where feasible, by Preferred Term in order of severity.

IMMUNE SYSTEM DISORDERS: Hypersensitivity/infusion reactions, including hypotension, pyrexia, tremor, chills, urticaria, rash, pruritus.

GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: Infusion site reactions, such as infusion site erythema, injection site streaking, burning sensation, infusion site urticaria.

Other adverse reactions/class reactions
Use appropriate section of your label to incorporate the following class like reactions.

The following adverse reactions have not been reported with this product but may occur:
- Hypernatraemia
- Hyperchloraemic metabolic acidosis
- Hyponatremia, which may be symptomatic

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continuing monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions https://nzphv.otago.ac.nz/reporting/
4.9 Overdose

Infusion of excess 0.9% Sodium Chloride infusion preparations may cause
- fluid overload
- sodium overload (which can lead to central and/or peripheral oedema)
- hypernatraemia, hyponatraemia
- other electrolyte abnormalities.

No specific antidotes to this preparation are known. Should overdose occur, prompt and careful clinical assessment is essential. Treat the symptoms and institute appropriate supportive measures as required.

**Symptoms of hypernatraemia**

Hypernatraemia may cause nausea, vomiting, diarrhoea and cramps, reduced salivation and lacrimation, increased thirst, hypotension, and tachycardia.

CNS effects include headache, dizziness, restlessness, weakness, muscle twitching or rigidity, respiratory paralysis, seizures, coma, and death.

**Treatment of hypernatraemia**

Treatment usually requires free water replacement. Plasma sodium concentrations should be corrected slowly. If hypernatraemia is severe, I.V. hypotonic or isotonic saline or 5% glucose may be used to restore normal plasma sodium concentrations at a rate of no more than 10 to 12mmol/L daily (0.5mmol/L per hour). If plasma sodium levels are greater than 200mmol/L or if the patient has renal impairment or is moribund, dialysis may be needed. Diazepam or other appropriate treatment may be required to treat convulsions.

**Symptoms of hyponatraemia**

Symptoms may include headache, confusion, nausea, vomiting, somnolence weakness, cerebral oedema, seizures, coma, respiratory arrest, and death.

**Treatment of hyponatraemia**

Acute hyponatraemia requires immediate assessment.

Symptomatic hyponatraemia associated with plasma sodium concentrations below 120mmol/L may require the administration of I.V. isotonic or hypertonic sodium chloride.

A loop diuretic may be required if there is fluid overload.

The aim is to render the patient asymptomatic, usually by restoring plasma sodium concentration to between 120mmol/L and 130mmol/L, at a rate of 10 to 12mmol/L in each 24 hour period.

Careful monitoring of plasma sodium concentrations and total body water is essential.

As in hypernatraemia, rapid correction of hyponatraemia is potentially dangerous.

If neurological deterioration occurs, further investigation by MRI imaging of brain, including brain stem, is indicated.

For advice on the management of overdose please contact the National Poisons Centre on phone number: 0800 764 766 [0800 POISON] in New Zealand (or 131126 in Australia).
5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: ATC Code: BLOOD SUBSTITUTE AND PERFUSION SOLUTIONS, IV SOLUTION ADDITIVES, ELECTROLYTE SOLUTIONS

The chemical name is sodium chloride.
Molecular formula is NaCl.
Molecular Weight is 58.44.
CAS is 7647-14-5).

Mechanism of Action
Sodium is the major cation of extracellular fluid and functions principally in the control of water distribution, fluid and electrolyte balance and osmotic pressure of body fluids. Chloride, the major extracellular anion, closely follows the physiological disposition of sodium cation in maintenance of acid-base balance, isotonicity and electrodynamical characteristic of the cells.

Thus, 0.9% Sodium Chloride infusion solution has a value as a source of water and electrolytes.

5.2 Pharmacokinetic properties

As 0.9% Sodium Chloride infusion solutions are directly administered to the systemic circulation by infusion, the bioavailability (absorption) of the active components is complete (100%).

5.3 Preclinical safety data

Carcinogenicity/mutagenicity

Studies with sodium chloride have not been performed to evaluate carcinogenic or mutagenic potential.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Water of injection, q.s.

6.2 Incompatibilities

Additives may be incompatible. See section 4.2. Suitability of potential additives has not been demonstrated. Complete information is not available. Those additives known to be incompatible should not be used. Before adding a substance or medication, verify that it is soluble and/or stable in water and that the pH range of 0.9% Sodium Chloride solution is appropriate. The instructions for use of the medication to be added and other relevant literature must be consulted. Consult with a pharmacist, if available.

If in the informed judgment of the doctor, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. After addition, check for a possible colour change and/or the appearance of precipitates, insoluble complexes or crystals. Do not store solutions containing additives. The stability of this product when mixed with additive has not been demonstrated, see section 4.4 and section 4.5.

6.3 Shelf life

Bag, plastic AVIVA 250mL 24 months from date of manufacture.
Bag, plastic AVIVA 500mL 24 months from date of manufacture.
Bag, plastic AVIVA 1,000mL 24 months from date of manufacture.
6.4 Special precautions for storage
Store at or below 25°C.

6.5 Nature and contents of container
0.9% Sodium Chloride infusions are supplied in VIAFLO plastic bags, in the following pack sizes:

<table>
<thead>
<tr>
<th>Item Code</th>
<th>Name of the active components [Concentrations (%, mmol/1000mL)]</th>
<th>Osmolarity(^{a}) (mOsmol/L)</th>
<th>Pack size (mL)</th>
<th>Shelf life (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSE1322</td>
<td>Sodium Chloride (0.9%, 154)</td>
<td>308 (300)</td>
<td>250</td>
<td>24</td>
</tr>
<tr>
<td>BSE1323</td>
<td>Sodium Chloride (0.9%, 154)</td>
<td>308 (300)</td>
<td>500</td>
<td>24</td>
</tr>
<tr>
<td>BSE1324</td>
<td>Sodium Chloride (0.9%, 154)</td>
<td>308 (300)</td>
<td>1000</td>
<td>24</td>
</tr>
</tbody>
</table>

Note: Osmolarity\(^{a}\) is a calculated figure.
The figures in the bracket are approximate Osmolarities (mOsmol/kg).

Not all pack sizes may be marketed.

6.6 Special precautions for disposal
Any unused product or waste material should be disposed of in accordance with local requirements.

7 MEDICINE SCHEDULE
General Sale Medicine.

8 SPONSOR
0.9% Sodium Chloride is distributed in New Zealand by:
Baxter Healthcare Ltd
33 Vestey Drive
Mt Wellington
Auckland 1060.

Baxter Healthcare Ltd
PO Box 14 062
Panmure
Auckland 1741

Phone (09) 574 2400.

0.9% Sodium Chloride is distributed in Australia by:
Baxter Healthcare Pty Ltd
1 Baxter Drive
Old Toongabbie, NSW 2146.

9 DATE OF FIRST APPROVAL
Date of publication in the New Zealand Gazette of consent to distribute the medicine: 15 May 2014.

10 DATE OF REVISION OF THE TEXT
### SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL</td>
<td>Trade name of plastic bag changed throughout data sheet from AVIVA to VIAFLO.</td>
</tr>
<tr>
<td>4.2</td>
<td>Inclusion of reference to section 6.2</td>
</tr>
<tr>
<td>4.6</td>
<td>Inclusion of Fertility heading, as suggested in “Tips for changing to the new data sheet format”.</td>
</tr>
<tr>
<td>5.1</td>
<td>Molecular formula, molecular weight and CAS number moved to this section.</td>
</tr>
<tr>
<td>6.3</td>
<td>Shelf life updated as per stability data.</td>
</tr>
<tr>
<td>6.5</td>
<td>Table updated with new item codes and shelf life.</td>
</tr>
<tr>
<td>10</td>
<td>Date of Revision of Text updated.</td>
</tr>
<tr>
<td>Footer</td>
<td>Reference to source document updated.</td>
</tr>
</tbody>
</table>

*Based on Australian PI most recent amendment DD MONTH YYYY, and ccsi429 2013 0507.*

*Please refer to the Medsafe website (www.medsafe.govt.nz) for most recent data sheet.*

*Baxter and VIAFLO are trademarks of Baxter International Inc.*